<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616733</url>
  </required_header>
  <id_info>
    <org_study_id>CS0777-A-U102</org_study_id>
    <secondary_id>IND 77,409</secondary_id>
    <nct_id>NCT00616733</nct_id>
  </id_info>
  <brief_title>12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients</brief_title>
  <official_title>An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week study to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability.</measure>
    <time_frame>12 weeks, with 4 weeks to follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response (lymphocyte counts Pharmacokinetics Exploratory efficacy based on brain MRI lesions)</measure>
    <time_frame>12 weeks, with 4 weeks to follow up.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-0777 tablets</intervention_name>
    <description>0.1 mg, once-weekly, for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-0777 tablets</intervention_name>
    <description>0.3 mg, once-weekly or once every 2 weeks, for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-0777 tablets</intervention_name>
    <description>0.6 mg, once-weekly or once every 2 weeks, for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of clinically isolated syndrome or a relapsing form(s) of MS, based on Poser
             or McDonald criteria (may include patients with secondary progressive disease)

          -  Clinical relapse within the past 3 years or a gadolinium enhancing lesion on a brain
             MRI scan within the past 12 months

          -  Baseline EDSS score of 0 - 6.5

          -  Female subjects who are sexually active, unless sterile or post-menopausal for at
             least 1 year, must be willing to use double-barrier contraception

        Exclusion Criteria:

          -  Primary progressive MS

          -  Any medical condition that predisposes to immunocompromise

          -  History of malignancy, tuberculosis, invasive fungal infections, herpes zoster
             infection (or shingles), or other opportunistic infection, or any current active
             infection

          -  Concurrent diagnosis of any other autoimmune disease (eg, rheumatoid arthritis or
             lupus)

          -  Treatment with cyclophosphamide or mitoxantrone within 6 months of study initiation

          -  Treatment with cyclosporine, azathioprine, methotrexate or other immunosuppressant
             within 3 months of study initiation

          -  Treatment with interferon beta or glatiramer acetate within 2 months of study
             initiation

          -  Prior treatment with natalizumab or rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>James Moberly, PhD, Senior Director, Clinical Development</name_title>
    <organization>Daiichi Sankyo, Inc.</organization>
  </responsible_party>
  <keyword>Multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

